Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1301 to 1350 of 1371 results for patients and public

  1. Vamorolone for treating Duchenne muscular dystrophy [ID4024]

    In development [GID-TA11135] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]

    In development [GID-TA10980] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development

  3. Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

    In development [GID-TA10165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Topical Antimicrobial dressings for wound care: Late stage assessment

    In development [GID-HTE10041] Expected publication date: TBC

    Health technology evaluations
    In development

  5. Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]

    In development [GID-TA11418] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  6. Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

    Awaiting development [GID-TA11491] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]

    Awaiting development [GID-TA11326] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Awaiting development [GID-TA11396] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    In development [GID-TA11228] Expected publication date: 25 September 2024

    Technology appraisal guidance
    In development

  10. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212

    In development [GID-TA11203] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  11. Cladribine for treating relapsing multiple sclerosis ID6263

    In development [GID-TA11293] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  12. Pegzilarginase for treating arginase-1 deficiency [ID4029]

    In development [GID-HST10054] Expected publication date: 30 October 2024

    Highly specialised technologies guidance
    In development

  13. Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]

    In development [GID-TA11039] Expected publication date: 21 August 2024

    Technology appraisal guidance
    In development

  14. Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]

    In development [GID-TA11167] Expected publication date: 04 June 2024

    Technology appraisal guidance
    In development

  15. Drug eluting stents for treating coronary heart disease: late stage assessment

    In development [GID-HTE10039] Expected publication date: TBC

    Health technology evaluations
    In development

  16. Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [ID5104]

    In development [GID-TA11006] Expected publication date: 29 May 2024

    Technology appraisal guidance
    In development

  17. Abaloparatide for treating osteoporosis in postmenopausal women [ID882]

    In development [GID-TA10071] Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]

    In development [GID-TA11355] Expected publication date: 09 July 2024

    Technology appraisal guidance
    In development

  19. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic device

    In development [GID-DG10080] Expected publication date: 22 August 2024

    Diagnostics guidance
    In development

  20. Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome

    In development [GID-DG10074] Expected publication date: 11 September 2024

    Diagnostics guidance
    In development

  21. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic device: diagnostics consultation

    We are listening to your views on this Diagnostics guidance. Comments close 4 June 2024.

    Diagnostics guidance
    In consultation

  22. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]

    In development [GID-TA11389] Expected publication date: 19 June 2024

    Technology appraisal guidance
    In development

  23. Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]

    In development [GID-TA10977] Expected publication date: TBC

    Technology appraisal guidance
    In development

  24. Upadacitinib for treating giant cell arteritis [ID6299]

    Awaiting development [GID-TA11330] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  25. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    Awaiting development [GID-TA11535] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  26. Depemokimab for treating chronic rhinosinusitis with nasal polyps TSID 12012

    Awaiting development [GID-TA11542] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  27. Sirolimus for treating angiofibroma from tuberous sclerosis complex in people 6 years and older [ID3990]

    In development [GID-TA10883] Expected publication date: 18 September 2024

    Technology appraisal guidance
    In development

  28. Avapritinib for treating advanced systemic mastocytosis ID3770

    In development [GID-TA11382] Expected publication date: TBC

    Technology appraisal guidance
    In development

  29. Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessment

    In development [GID-HTE10030] Expected publication date: 15 August 2024

    Health technology evaluations
    In development

  30. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441

    Awaiting development [GID-TA11544] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  31. Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: TBC

    Technology appraisal guidance
    In development

  32. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development [GID-TA11253] Expected publication date: TBC

    Technology appraisal guidance
    In development

  33. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    Awaiting development [GID-TA11093] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  34. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442

    Awaiting development [GID-TA11424] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  35. Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma [ID6325]

    In development [GID-TA11545] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  36. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development [GID-TA11455] Expected publication date: TBC

    Technology appraisal guidance
    In development

  37. Adalimumab for treating early Dupuytren's contracture TS ID 11870

    Awaiting development [GID-TA11363] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  38. Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]

    In development [GID-TA10655] Expected publication date: 11 September 2024

    Technology appraisal guidance
    In development

  39. News

    home rather than hospital and improves the length and quality of life for patients. 24 April 2024

  40. NICE

    NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

  41. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]

    In development [GID-TA10813] Expected publication date: TBC

    Technology appraisal guidance
    In development

  42. Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]

    In development [GID-TA11390] Expected publication date: 24 July 2024

    Technology appraisal guidance
    In development

  43. Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235

    In development [GID-TA11246] Expected publication date: TBC

    Technology appraisal guidance
    In development

  44. Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome: diagnostics consultation

    We are listening to your views on this Diagnostics guidance. Comments close 5 June 2024.

    Diagnostics guidance
    In consultation

  45. Mirikizumab for treating moderately to severely active Crohn's disease ID6244

    In development [GID-TA11267] Expected publication date: TBC

    Technology appraisal guidance
    In development

  46. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    In development [GID-TA11086] Expected publication date: TBC

    Technology appraisal guidance
    In development

  47. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]

    In development [GID-TA11288] Expected publication date: TBC

    Technology appraisal guidance
    In development

  48. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development [GID-TA11546] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  49. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    Awaiting development [GID-TA11008] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  50. Dapagliflozin for treating chronic kidney disease [ID6411]

    In development [GID-TA11547] Expected publication date: 12 February 2025

    Technology appraisal guidance
    In development